Joaquim Bellmunt
Beth Israel Deaconess Medical Center
725 Papers
5.2K Citations
Joaquim Bellmunt is an academic researcher from Beth Israel Deaconess Medical Center. The author has contributed to research in topics: Medicine & Bladder cancer. The author has an hindex of 82, co-authored 660 publications. Previous affiliations of Joaquim Bellmunt include University of Cambridge & Brigham and Women's Hospital.
Chat about Author
Papers
Nomogram to assess benefit of new over historical agents as salvage therapy for metastatic urothelial carcinoma (mUC) in non-randomized trials: Effect of atezolizumab on 12-month survival.
Gregory R. Pond,Guru Sonpavde,Jonathan E. Rosenberg,Toni K. Choueiri,Joaquim Bellmunt,Ashley Marie Regazzi,Stephanie A. Mullane,Andrea Necchi,Daniele Raggi,Jae-Lyun Lee,Soon Il Lee,Joe Simpson,Christina Louise Derleth,Shih-Wen Lin,Dean F. Bajorin +14 more
TL;DR: A nomogram was developed using prognostic variables from phase 2 trials of historical agents to estimate 12 month survival to which observed survival in single arm trials could be compared.
3
Frequent dose delays and growth factor requirements with the sequential doxorubicin-CMF schedule
Antoni Ribas,Joan Albanell,Joaquim Bellmunt,Begoña Bermejo,Enrique Gallardo,R. Vera,R. Bodi,Luis-Alfonso Solé-Calvo +7 more
TL;DR: Doxorubicin for four cycles plus cyclophosphamide, methotrexate and 5-fluorouracil for eight cycles is an effective adjuvant regimen for breast cancer patients with more than three involved axillary lymph nodes and growth factors are needed to maintain dose intensity similar to that achieved in the original trial.
3
285TiP DANUBE: A Phase 3 randomised study of first-line durvalumab (MEDI4736) ± tremelimumab vs standard of care (SoC) chemotherapy (CT) in patients (pts) with Stage IV urothelial carcinoma (UC)
S.H. Park,Daniel Castellano,Daniel P. Petrylak,Matthew D. Galsky,M.S. van der Heijden,Yohann Loriot,Osamu Ogawa,W-C Su,W. Huang,Wendy Levin,Salvatore Ferro,Yong Ben,Joaquim Bellmunt,Thomas Powles +13 more
3
Cyclophosphamide, methotrexate, and chronic oral tegafur modulated by folinic acid in the treatment of patients with advanced breast carcinoma
Antoni Ribas,Joan Albanell,Luis-Alfonso Solé-Calvo,Enrique Gallardo,Joaquim Bellmunt,R. Vera,Rosó Vidal,J Carulla,José Baselga +8 more
TL;DR: Chronic oral tegafur modulated by folinic acid has antitumor activity in patients with metastatic breast carcinoma resistant to 5‐fluorouracil or doxorubicin‐based regimens.
3